Ascletis Pharma Inc. (HKG:1672)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.65
+0.44 (3.33%)
At close: Dec 5, 2025
671.19%
Market Cap 13.54B
Revenue (ttm) 2.59M
Net Income (ttm) -283.33M
Shares Out 991.97M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,876,000
Average Volume 7,693,599
Open 13.30
Previous Close 13.21
Day's Range 13.08 - 13.75
52-Week Range 1.65 - 18.75
Beta 0.55
RSI 56.25
Earnings Date Nov 16, 2025

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of prima... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 231
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1672
Full Company Profile

Financial Performance

In 2024, Ascletis Pharma's revenue was 1.28 million, a decrease of -97.73% compared to the previous year's 56.60 million. Losses were -300.94 million, 108.0% more than in 2023.

Financial numbers in CNY Financial Statements

News

There is no news available yet.